Table 1.

Patient demographics and baseline characteristics.

All patients N = 339
Median age at baseline, y (range)62 (24, 86)
Sex
 Male170 (50)
 Female169 (50)
ECOG performance score at baseline
 073 (22)
 1262 (77)
 24 (1)
Disease stage at initial diagnosis
 Ia8 (2)
 Ib5 (1)
 IIa8 (2)
 IIb5 (1)
 IIIa38 (11)
 IIIb45 (13)
 IV225 (66)
 Missing5 (1)
Prior lines of therapy
 2261 (77)
 352 (15)
 ≥426 (8)
Prior systemic therapies
 Platinum-containing therapies339 (100)
 Topotecan133 (39)
 PD-1 inhibitor58 (17)
 All other therapies148 (44)
Response to 1L therapy
 Sensitivea248 (73)
 Resistantb58 (17)
 Refractoryc20 (6)
 Undetermined13 (4)
Time to progression on 2L therapy
 ≤3 months113 (33)
 >3 months226 (67)
Tumor biopsy used for screening
 Primary lesion161 (47)
 Metastatic lesion169 (50)
 Unknown/missing9 (3)
History of brain metastases
 Yes134 (40)
 No205 (60)
History of pleural effusions
 Yes85 (25)
 No254 (75)
DLL3 status
 DLL3-high (≥75%)238 (70)
 DLL3-positive (≥25%)287 (85)
 DLL3 discordant (0% ≤ to ≤ 24%)28 (8)
 Missing24 (7)
  • NOTE: Data shown are n (%) unless otherwise indicated.

  • Abbreviations: 1L, first-line; 2L, second-line; DLL3, Delta-like 3 protein; ECOG, Eastern Cooperative Oncology Group.

  • aDefined as treatment-free interval (TFI) between first and second line of therapy of ≥90 days.

  • bDefined as TFI between first and second line of therapy of <90 days.

  • cDefined as best response to first-line therapy of PD.